Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

Similar articles for PubMed (Select 24012420)


Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2.

Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG, Kotarski J, Tarkowski R, Wicha M, Cho K, Giordano T, Liu R, Zou W.

Immunity. 2013 Sep 19;39(3):611-21. doi: 10.1016/j.immuni.2013.08.025. Epub 2013 Sep 5.


BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.

May T, Yang J, Shoni M, Liu S, He H, Gali R, Ng SK, Crum C, Berkowitz RS, Ng SW.

Neoplasia. 2013 Jun;15(6):600-8.


Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.

Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J, Ren X.

J Immunol. 2013 Apr 1;190(7):3783-97. doi: 10.4049/jimmunol.1201449. Epub 2013 Feb 25.


Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.

Höchst B, Schildberg FA, Sauerborn P, Gäbel YA, Gevensleben H, Goltz D, Heukamp LC, Türler A, Ballmaier M, Gieseke F, Müller I, Kalff J, Kurts C, Knolle PA, Diehl L.

J Hepatol. 2013 Sep;59(3):528-35. doi: 10.1016/j.jhep.2013.04.033. Epub 2013 May 9.


C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.

Barroilhet L, Yang J, Hasselblatt K, Paranal RM, Ng SK, Rauh-Hain JA, Welch WR, Bradner JE, Berkowitz RS, Ng SW.

Oncogene. 2013 Aug 15;32(33):3896-903. doi: 10.1038/onc.2012.380. Epub 2012 Sep 3.


Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.

Birts CN, Harding R, Soosaipillai G, Halder T, Azim-Araghi A, Darley M, Cutress RI, Bateman AC, Blaydes JP.

Biol Cell. 2010 Jan;103(1):1-19. doi: 10.1042/BC20100067.


Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis.

Ye XZ, Yu SC, Bian XW.

J Genet Genomics. 2010 Jul;37(7):423-30. doi: 10.1016/S1673-8527(09)60061-8.


Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.

Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P.

Blood. 2011 Nov 17;118(20):5498-505. doi: 10.1182/blood-2011-07-365825. Epub 2011 Oct 4.


PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.

Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P.

Cancer Res. 2011 Dec 15;71(24):7463-70. doi: 10.1158/0008-5472.CAN-11-2449. Epub 2011 Oct 24.


Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration.

Wang Y, Liu F, Mao F, Hang Q, Huang X, He S, Wang Y, Cheng C, Wang H, Xu G, Zhang T, Shen A.

J Biol Chem. 2013 Mar 29;288(13):9028-34. doi: 10.1074/jbc.M112.432005. Epub 2013 Feb 7.


Both miR-17-5p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression.

Zhang M, Liu Q, Mi S, Liang X, Zhang Z, Su X, Liu J, Chen Y, Wang M, Zhang Y, Guo F, Zhang Z, Yang R.

J Immunol. 2011 Apr 15;186(8):4716-24. doi: 10.4049/jimmunol.1002989. Epub 2011 Mar 7.


Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.

Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA.

Blood. 2008 Apr 15;111(8):4233-44. doi: 10.1182/blood-2007-07-099226. Epub 2008 Feb 13.


Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.

Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, Zhu J, Wei H, Zhao K.

PLoS One. 2013;8(2):e57114. doi: 10.1371/journal.pone.0057114. Epub 2013 Feb 20.


Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL.

Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S.

Blood. 2011 May 19;117(20):5381-90. doi: 10.1182/blood-2010-11-321752. Epub 2011 Mar 30.


CtBP2 could promote prostate cancer cell proliferation through c-Myc signaling.

Zhang C, Gao C, Xu Y, Zhang Z.

Gene. 2014 Aug 1;546(1):73-9. doi: 10.1016/j.gene.2014.05.032. Epub 2014 May 14.


MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN.

Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F, Wang X, Wang J, Yu H, Cao X, Wang Q.

J Immunol. 2012 Jun 1;188(11):5500-10. doi: 10.4049/jimmunol.1103505. Epub 2012 Apr 27.


MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P.

Int Immunopharmacol. 2011 Jul;11(7):856-61. doi: 10.1016/j.intimp.2011.01.030. Epub 2011 Feb 11.


Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice.

Godoy HE, Khan AN, Vethanayagam RR, Grimm MJ, Singel KL, Kolomeyevskaya N, Sexton KJ, Parameswaran A, Abrams SI, Odunsi K, Segal BH.

PLoS One. 2013 Jul 26;8(7):e69631. doi: 10.1371/journal.pone.0069631. Print 2013.


Myeloid-derived suppressor cells in breast cancer.

Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE 3rd.

Breast Cancer Res Treat. 2013 Jul;140(1):13-21. doi: 10.1007/s10549-013-2618-7. Epub 2013 Jul 5. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk